We’re all familiar with the suburban horror story in which a well-intentioned camper returns home from their summer trip with a Lyme disease souvenir. In fact, it affects more than 200,000 people each year. According to a recent FierceBiotech article, those unlucky folks who contract the tick-born illness will be diagnosed quicker thanks to a new streamlined diagnostic test that was just cleared by the FDA.
The test, developed by Zeus Scientific, runs two enzyme immunoassays either concurrently or sequentially to detect the disease, as opposed to the traditional two-step process. The new method is easier to interpret by a clinical laboratory and will likely improve confidence in diagnosing a condition where early detection is vital to ensure the best outcome.